Cosmetic composition for skin calming

Abstract

The present application relates to a cosmetic composition, and more particularly, to a cosmetic composition comprising an amino acid-amino acid eutectic mixture and Troxerutin as an effective ingredient, thereby providing an effect of inhibiting inflammation and relieving / reducing skin irritation.

Description

Technical Field

[0001] This invention relates to a cosmetic composition for skin soothing, and more specifically, to a technology that provides a composition comprising an amino acid-amino acid eutectic mixture and troxerutin as active ingredients, exhibiting anti-inflammatory and skin-irritation-relieving / reducing effects, thereby providing a low-irritant topical skin agent or a topical skin soothing agent. Background Technology

[0002] Consumers using cosmetics have identified a demand for effectively soothing sensitive or irritated skin. Furthermore, a large proportion of these consumers identify as having sensitive skin. As a result, the market for cosmetics specifically formulated for sensitive skin or skin-soothing products is expanding. However, there is a lack of research on effective materials or synergistic combinations of these materials that can soothe sensitive skin.

[0003] While previously developed eutectic blends (Korean Patent No. 10-2411385) have shown excellent effects in promoting skin regeneration, collagen synthesis, and improving skin elasticity, they are insufficient to soothe sensitive or irritated skin.

[0004] Troxerutin, derived from the Japanese sophora tree (Sophora japonica), is reported to function as an antioxidant when applied topically, thus removing reactive oxygen species and preventing oxidative stress. It is also known to protect the skin from UVB damage. However, troxerutin suffers from insufficient skin penetration.

[0005] Against this backdrop, the inventors conducted in-depth research to enhance the skin-soothing effect of amino acid-amino acid eutectic mixtures and improve the skin penetration of troxerutin. As a result, by using amino acid-amino acid eutectic mixtures and troxerutin together, the synergistic effect between the corresponding substances was confirmed, thus completing the present invention. Summary of the Invention

[0006] Technical issues

[0007] One object of the present invention is to provide a cosmetic composition comprising an amino acid-amino acid eutectic mixture and troxerutin as an active ingredient.

[0008] Technical solution

[0009] The specific details are explained below. Furthermore, the various descriptions and embodiments disclosed in this invention can also be applied to other descriptions and embodiments. That is, all combinations of the various elements disclosed in this invention fall within the scope of this invention. Additionally, the scope of this invention should not be considered limited by the specific descriptions below.

[0010] To achieve the aforementioned objective, a cosmetic composition is provided comprising an amino acid-amino acid eutectic mixture and troxerutin as an active ingredient.

[0011] To achieve the aforementioned objective, a method for skin soothing or anti-inflammatory is provided, comprising the step of treating the skin with a composition containing an amino acid-amino acid eutectic mixture and troxerutin as an active ingredient.

[0012] To achieve the aforementioned objective, a method for skin soothing or anti-inflammatory is provided, comprising the step of applying a composition containing an amino acid-amino acid eutectic mixture and troxerutin as an active ingredient to a subject.

[0013] To achieve the aforementioned objectives, we provide a composition comprising an amino acid-amino acid eutectic mixture and troxerutin as an active ingredient for use in the preparation of cosmetics, food products, or tertiary pharmaceutical products for skin soothing or anti-inflammatory purposes.

[0014] The present invention will now be described in more detail.

[0015] The term "skin calming" in this invention refers to calming irritated sensitive skin, inhibiting the expression of inflammatory factors in the skin, and giving the skin a cooling sensation.

[0016] The term "anti-inflammatory" in this invention refers to something used to suppress and prevent inflammation, thereby protecting the skin and relieving and combating inflammation.

[0017] The term "eutectic mixture" in this invention refers to a eutectic compound formed by the combination of polar compounds, which may contain amino acids and may be an amino acid-amino acid eutectic mixture prepared according to Korean Patent No. 10-2626486.

[0018] The aforementioned amino acid-amino acid eutectic mixtures can be in the form of amino acid-amino acid or amino acid-amino acid-more than one solvent, depending on the types of amino acids they contain, which is determined by the characteristics between the paired amino acids.

[0019] Specifically, the polar compounds should exhibit differences in polarity, and the aforementioned amino acids can be polar compounds. In the case of polar amino acids, polar amino acids, acidic amino acids, and basic amino acids can be included. Polar amino acids can include serine, threonine, cysteine, tyrosine, asparagine, and glutamine; acidic amino acids can include aspartic acid and glutamic acid; and basic amino acids can include arginine, histidine, and lysine. Preferably, they can be eutectic mixtures of arginine glutamate or serine arginine.

[0020] The term "arginine" in this invention refers to the chemical formula C6H4O. 14 L-arginine is a basic amino acid, found in N4O2. As an α-amino acid, L-arginine is a constituent amino acid of proteins, including protamine, a protein found in fish sperm. It is also a component of the ornithine cycle, a metabolic pathway in organisms, and is broken down into urea and ornithine by arginase. It is a semi-essential amino acid required for the growth of children and animals. Specifically, arginine can be a basic amino acid.

[0021] The term "glutamic acid" in this invention is an acidic α-amino acid abbreviated as Glu,E, with the chemical formula C5H9NO4 and a molecular weight of 147.13. It was first discovered in gluten. L-glutamic acid is widely distributed in general proteins, especially abundant in cereal proteins. Specifically, the aforementioned glutamic acid can be an acidic amino acid.

[0022] Based on 100 parts by weight of the overall eutectic mixture, the total content of amino acids in the aforementioned eutectic mixture may be 1 to 100 parts by weight, 5 to 90 parts by weight, 10 to 80 parts by weight, 15 to 70 parts by weight, 20 to 65 parts by weight, 30 to 60 parts by weight, 35 to 55 parts by weight, 40 to 50 parts by weight, or 42 to 47 parts by weight, but is not limited thereto.

[0023] The above-mentioned amino acid-amino acid eutectic mixture may further contain one or more solvents.

[0024] The solvent mentioned above can be one or more solvents selected from water, ethanol, methanol, and acetone, but is not limited to these, and can be a solvent capable of dissolving amino acids.

[0025] In this invention, the solvent described above may be included in 0 to 98 parts by weight relative to 100 parts by weight of the overall eutectic mixture.

[0026] The case where the solvent content in the aforementioned eutectic mixture is 0% can result in a stable eutectic mixture being formed in an anhydrous form. When the solvent content exceeds 98 parts by weight, the formation of a eutectic mixture may be hindered due to the instability of hydrogen bonds, thus reverting to a general mixture form. In this case, the skin penetration of troxerutin may decrease, making it difficult to achieve the desired effect.

[0027] Preferably, relative to 100 parts by weight of the total eutectic mixture, the eutectic mixture of the present invention may contain 10 to 90 parts by weight, 20 to 80 parts by weight, 30 to 70 parts by weight, or 40 to 60 parts by weight of solvent, but is not limited thereto.

[0028] The required ratio of substances in a eutectic mixture can be determined based on the charge of the molecules constituting the eutectic mixture, the type and number of functional groups of the molecules, and the polarity of the molecules or functional groups. Alternatively, the required ratio of substances in a eutectic mixture can be determined based on the size or similarity of the molecules.

[0029] Regarding the eutectic mixture formation ratio, the molar concentration of each amino acid can be from 10:1 to 10:100.

[0030] Preferably, regarding the above-mentioned eutectic mixture formation ratio, the molar concentration of each amino acid can be from 1:1 to 1:3.

[0031] To reduce skin irritation and other discomfort when applied to the skin, the acidity of the eutectic mixture according to the present invention can be adjusted to a value of pH 3 to pH 10. The eutectic mixture according to the present invention can be prepared within the range where the amino groups of amino acids are structurally charged, and the corresponding range can be above pH 3. For example, the eutectic mixture can be adjusted to have a weakly acidic to neutral acidity, such as pH 4 to pH 9, pH 5 to pH 8, or pH 6 to pH 7.

[0032] The eutectic mixture of the present invention, by containing an amino acid-amino acid or amino acid-amino acid-one or more solvents, can increase the stability of the composition by utilizing the melting point reduction and solubility increase characteristics of the eutectic mixture.

[0033] Typically, the skin benefits of amino acids increase as the pH decreases, which is why cosmetics have traditionally maintained a low pH. However, the eutectic blend of the present invention reduces skin irritation that may occur at weakly acidic to neutral pH levels while increasing the skin permeability of amino acids. Thus, even at weakly acidic to neutral pH levels, the increased permeability allows the amino acids to maintain their high efficacy, similar to cosmetics that have traditionally maintained a low pH.

[0034] The cosmetic composition according to the present invention may contain, relative to the total weight of the cosmetic composition, 0.001 to 50 parts by weight, for example 0.01 to 50 parts by weight, 0.05 to 40 parts by weight, 0.05 to 30 parts by weight, 0.1 to 30 parts by weight, 0.1 to 25 parts by weight, 0.5 to 25 parts by weight, 0.1 to 50 parts by weight, 1 to 35 parts by weight, 5 to 30 parts by weight, 0.5 to 40 parts by weight, 1 to 30 parts by weight, 5 to 28 parts by weight, 8 to 25 parts by weight, 1 to 50 parts by weight, 5 to 40 parts by weight, 10 to 35 parts by weight, 15 to 25 parts by weight, 18 to 25 parts by weight, 15 to 20 parts by weight, 10 to 20 parts by weight, 10 to 30 parts by weight, 10 to 40 parts by weight, 15 to 35 parts by weight, 20 to 30 parts by weight, and 1 to 10 parts by weight of the above-described eutectic mixture, but is not limited thereto. The content of the above-mentioned eutectic mixture can be adjusted to a dosage form suitable for cosmetic compositions.

[0035] The term "rutinoside" in this invention refers to a semi-synthetic substance derived from the flavonoid rutinoside of the Japanese locust tree, which inhibits the secretion of inflammatory mediators and white blood cells involved in inflammatory metabolic responses, as well as factors acting on vascular endothelial cells.

[0036] Specifically, it has been reported to function as an antioxidant when applied topically, thereby removing reactive oxygen species and preventing oxidative stress, and is known to protect the skin from UVB damage. However, troxerutin has the drawback of low skin penetration.

[0037] Therefore, the present invention includes an amino acid-amino acid eutectic mixture and troxerutin as active ingredients, and specific embodiments have confirmed the synergistic effects of skin soothing and anti-inflammatory effects when used together.

[0038] The content of troxerutin may be 0.0001 to 2 parts by weight relative to 100 parts by weight of the total composition.

[0039] When the content of the above-mentioned troxerutin is 0.0001 to 2 parts by weight relative to 100 parts by weight of the whole composition, it can significantly increase the anti-inflammatory factor inhibition effect or NO inhibition effect.

[0040] The ratio of troxerutin to the eutectic mixture can be from 1:0.1 to 1:100, preferably from 1:0.2 to 1:50, and more preferably from 1:1 to 1:20.

[0041] Compared with troxerutin alone, the above composition can increase the skin penetration of troxerutin by 1.5 to 10 times.

[0042] Specifically, when the above composition is applied to the skin, compared to applying troxerutin alone, the skin penetration rate can be increased by 1.5 to 10 times. Preferably, it can be increased by 2 to 10 times.

[0043] It has been confirmed that when troxerutin is used alone, its skin penetration rate may be less than 0.1%, which may result in minimal anti-inflammatory effect of the cosmetic composition. However, when the cosmetic composition of the present invention is used together with the above-mentioned eutectic mixture, the skin penetration rate of troxerutin is increased by 1.5 to 10 times compared with its use alone, thereby improving the skin calming and anti-inflammatory effects and exhibiting a synergistic effect.

[0044] The cosmetic composition according to the present invention may further comprise an oil phase component.

[0045] The aforementioned oil phase components can be one or more oils or waxes. The aforementioned oils and waxes can be any oils and waxes commonly used in the art as cosmetic ingredients. For example, silicone oils, ester oils, triglyceride oils, hydrocarbon oils, or vegetable oils can be used as the aforementioned oils, and one or more of these components can be formulated as needed.

[0046] For example, as the aforementioned silicone-based oil, silicone-based flow oils or silicone-based crosslinked polymers dispersed in the oil can be used. For example, as silicone-based flow oils, cyclopentasiloxane, cyclohexylsiloxane, cycloheptane, cyclopolymethylsiloxane, cyclophenylpolymethylsiloxane, cyclotetrasiloxane, cyclotrisiloxane, polydimethylsiloxane, capryl dimethicone, and caprylyl polytrimethylsiloxane can be used. Trimethicone, octanoyl polymethylsiloxane, cetearyl polymethylsiloxane, hexadecyl polymethylsiloxane, hexyl polymethylsiloxane, lauryl polymethylsiloxane, myristyl polymethylsiloxane, phenyl polymethylsiloxane, stearyl polymethylsiloxane, stearyl polydimethylsiloxane, trifluoropropyl polymethylsiloxane, cetyl polydimethylsiloxane, diphenylsiloxyphenyl polytrimethylsiloxane, dimethyl polysiloxane, methylphenyl polysiloxane, decamethylcyclopentane, methyl polytrimethylsiloxane, or phenyl polytrimethylsiloxane, etc. The above silicone oil components can be used alone or in mixtures of two or more oils. As a silicon-based crosslinking polymer, polydimethylsiloxane crosslinking polymers, polydimethylsiloxane / vinyl polydimethylsiloxane crosslinking polymers, polydimethylsiloxane PEG-10 / 15 crosslinking polymers, or PEG-12 polydimethylsiloxane / PPG-20 crosslinking polymers can be used, but are not limited to these.

[0047] As ester oils, the following can be used: ascorbyl palmitate, ascorbyl linoleate, ascorbyl stearate, diisostearyl malate, benzyl benzoate, benzyl laurate, butylene glycol dicaprylate / didecanoate, butylene glycol diisonononate, butylene glycol laurate, butylene glycol stearate, butyl isostearate, cetearyl isonononate, cetearyl nonanoate, cetearyl octanoate, cetearyl ethylhexanoate, cetearyl isonononate, ethylhexyl octanoate / decanoate, ethylhexyl isonononate, ethylhexyl isostearate, ethylhexyl laurate, hexyl laurate, octyl dodecyl isostearate, isostearyl isopropyl isostearate, isostearyl isonononate, isostearyl isostearyl... Fatty acid esters, isocetyl ethylhexanoate, neopentyl glycol didecanoate, neopentyl glycol diethylhexanoate, neopentyl glycol diisonononate, neopentyl glycol diisostearate, pentaerythritol stearate, pentaerythritol tetraethylhexanoate, dipentaerythritol hexaate, polyglycerol-2 diisostearate, polyglycerol-2 sesquiisostearate, polyglycerol-2 isostearate, polyglycerol-2 tetraisostearate, polyglycerol-2 triisostearate, polyglycerol-3 diisostearate, polyglycerol-3 isostearate, polyglycerol-4 diisostearate, polyglycerol-4 isostearate, polyglycerol-6 diisostearate, polyglycerol-6 sesquiisostearate, or triisooctanoic acid glyceride, etc.

[0048] As triglyceride oils, C8-C12 triglycerides, C12-C18 triglycerides, caprylic / capric / triglycerides, caprylic / capric / lauric triglycerides, C10-C40 isoalkyl triglycerides, C10-C18 triglycerides, triacetyl hydroxystearate, soybean glycerides, tris(2-3 ...

[0049] As a hydrocarbon oil, liquid paraffin, mineral oil, paraffin, petrolatum, microcrystalline wax or squalene can be used.

[0050] As a vegetable oil, you can use avocado oil, wheat germ oil, rosehip oil, shea butter, almond oil, olive oil, macadamia oil, argan oil, meadowfoam oil, sunflower oil, castor oil, camellia oil, corn oil, safflower oil, soybean oil, rapeseed oil, macadamia nut oil, jojoba oil, palm oil, palm kernel oil, or coconut oil.

[0051] As the aforementioned waxes, all waxes commonly used in cosmetics, such as hydrocarbon waxes, plant-based waxes, or silicone waxes, can be used. For example, they may include candelilla wax, carnauba wax, rice wax, beeswax, lanolin, ceresin wax, pure ceresin wax, paraffin wax, microcrystalline wax, C30-C45 alkyl dimethylsilyl polypropylene silsesquioxane, ethylene / propylene copolymer, or polyethylene wax, but are not limited to these.

[0052] There are no particular limitations on the content of the above-mentioned oil phase components, and they can be included in the composition in the remaining amount other than the eutectic mixtures mentioned above.

[0053] The above-mentioned cosmetic composition can be used to soothe the skin.

[0054] The cosmetic compositions of the present invention may further comprise all kinds of ingredients that can be used in conventional cosmetics, such as: moisturizers, such as glycerin, butylene glycol, propylene glycol, hexanediol, methyl gluceth-20, diglyceride, ethylhexylglycerin; UV blockers, such as ethylhexyl methoxycinnamate, ethylhexyl salicylate, ethylhexyl triazine, octocrylene, diethylhexyloxyphenol methoxyphenyl triazine; pH adjusters, such as triethanolamine; thickeners, such as carbomer, xanthan gum, acrylate / C10-30 alkyl acrylate crosspolymers, hyaluronic acid; preservatives, such as phenoxyethanol, methylparaben, propylparaben; antioxidants, such as BHT, ethyl ascorbic acid ether, ascorbic acid; skin conditioning agents, such as β-glucan; surfactants, such as cetearyl glucoside, sorbitan stearate; fragrances or colorants, and there are no limitations on their composition.

[0055] The ingredients described above in the cosmetic composition according to the present invention are preferably included in the cosmetic composition of the present invention within the range not exceeding the maximum usage specified in the "Cosmetic Safety Technical Specifications" stipulated by the Chinese government.

[0056] The cosmetic compositions according to the present invention can also be prepared in any dosage form conventionally prepared in this field. For example, the cosmetic compositions described above can have the following dosage forms: lotions such as softening lotions or nourishing lotions, spray-type lotions, lotions such as facial lotions and body lotions, creams such as nourishing creams, moisturizing creams, and eye creams, sticks, serums, cosmetic ointments, sprays, gels, masks, sunscreens, makeup bases, liquid or spray-type foundations, powders, makeup removers such as facial cleansers and makeup remover oils, and cleansing agents such as facial washes, soaps, and shower gels, but are not limited thereto.

[0057] In one specific example, the dosage form of the above cosmetic composition may be a toner / skin solubilizer, an O / W emulsion, an O / W cream, or a W / S cream.

[0058] In this invention, the term "solvent-type" refers to a dosage form in which a small amount of oil component is transparently dissolved in water. It is a dosage form in which the diameter of the oil droplets is smaller than the wavelength of visible light, thus not hindering the direct propagation of light and preventing scattering or reflection, thereby exhibiting a transparent property. Cosmetic compositions having the above-mentioned solubilizing properties can be transparent skin lotions, toners, hair tonics, or hair liquids, but are not limited to these types.

[0059] The cosmetic composition of the present invention can be used according to conventional methods, and the frequency of use can be varied according to the user's skin condition or preference.

[0060] Another aspect of the present invention for achieving the aforementioned objectives provides an anti-inflammatory composition comprising an amino acid-amino acid eutectic mixture and troxerutin as an active ingredient.

[0061] In one specific embodiment, it was confirmed that the cosmetic composition of the present invention has increased skin permeability compared to the use of troxerutin alone, thereby solving the problem of low skin permeability of troxerutin, and can provide a cosmetic composition with higher skin-soothing and anti-inflammatory effects.

[0062] The advantages and features of the present invention, as well as the methods for realizing them, will become clear when referring to the experimental and preparation examples described in detail below. However, the present invention is not limited to the experimental and preparation examples disclosed below, but can be implemented in many different forms, and is provided only to make the disclosure of the invention thorough and to fully illustrate the scope of the invention to those skilled in the art.

[0063] Invention Effects

[0064] The skin-soothing and anti-inflammatory cosmetic composition of the present invention comprises a eutectic mixture and troxerutin, exhibiting the effects of increasing troxerutin penetration, inhibiting inflammation, and relieving skin irritation, thereby providing a low-irritant skin topical agent or a skin-soothing topical agent. Detailed Implementation

[0065] The present invention will now be described in more detail through embodiments. These embodiments are only used to illustrate the present invention more specifically, and the scope of the present invention is not limited to these embodiments.

[0066] Example 1: Confirmation of NO expression inhibition effect

[0067] To confirm the anti-inflammatory effect of the cosmetic composition of the present invention, the NO generation inhibition effect of each prepared sample was evaluated using Raw 264.7 cells.

[0068] Specifically, as shown in Table 1 below, each sample was used to pretreat Raw 264.7 cells for 30 minutes, followed by incubation with 500 ng / ml lipopolysaccharide (LPS) for 18 hours. After incubation, the supernatant was collected, transferred to a 96-well plate, and GRIESS reagent was added. The reaction was carried out at room temperature for 15 minutes. The absorbance at 540 nm was measured using an ELISA reader, and the NO production inhibition capacity was calculated according to the following formula. The results are shown in Table 1.

[0069] NO generation inhibition capacity (%) = {1 - (NO generation when sample is added ÷ NO generation when no sample is added)} × 100 Positive control group: 100 μM L-NMMA (80.9% NO generation inhibition rate) Negative control group: RAW 264.7 cells treated with LPS only. [Table 1]

[0070] As shown in Table 1 above, when troxerutin or arginine glutamate eutectic mixture was used alone, no inhibitory effect on the production of the inflammatory factor NO was observed. However, in the combination of 'troxerutin + arginine glutamate eutectic mixture' of the present invention, the ability to inhibit NO production was confirmed, thereby confirming the anti-inflammatory effect of the cosmetic composition of the present invention.

[0071] Example 2: Confirmation of the inhibitory effect of cytokine IL-1β expression

[0072] To confirm the anti-inflammatory effects of the eutectic mixture of troxerutin and arginine glutamate, the inhibitory effect on the production of capsaicin-induced sensitive stimuli (cytokines) was evaluated in human keratinocytes.

[0073] Specifically, as shown in Table 2 below, each sample was pretreated with a human keratinocyte cell line for 1 hour, then 50 μM capsaicin was added, and the cells were cultured for 24 hours. After culture, RNA was extracted, cDNA was synthesized, and polymerase chain reaction (real-time PCR) was performed to measure the amount of IL-1β. The inhibitory capacity for the production of the sensitive inflammatory cytokine (IL-1β) was calculated using the following formula, and the results are shown in Table 2.

[0074] Cytokine production inhibition capacity (%) = [1 - (gene expression fold with sample addition ÷ gene expression fold without sample addition)] × 100 Negative control group: Human keratinocyte cell line treated with capsaicin only [Table 2]

[0075] As shown in Table 2 above, it was confirmed that when the arginine glutamate eutectic mixture was used alone, the expression of the inflammatory factor IL-1β was increased. Compared with the IL-1β expression inhibition rate when troxerutin was used alone, the inflammatory factor inhibition effect of the troxerutin + arginine glutamate eutectic mixture combination of the present invention was more than 2 times better. It was also confirmed that a synergistic effect was expressed by using the arginine glutamate eutectic mixture together with troxerutin.

[0076] Example 3: Skin Permeability Evaluation

[0077] The skin penetration of the eutectic mixture of troxerutin and arginine glutamate was evaluated.

[0078] Specifically, skin adsorption was evaluated using a Franz Cell (Labfine, FCDV-15). A transdermal diffusion testing membrane (Merck, Start-M 25mm) capable of predicting skin permeability was placed between the donor chamber and the receiver chamber, and 3 ml of PBS solution was added to the receiver chamber.

[0079] The evaluation method is as follows: 100 μl of [1 wt% troxerutin] and [1 wt% troxerutin + 10 wt% arginine glutamate eutectic mixture] were applied to the membrane, respectively. The membrane was then rolled 10 times over 30 seconds with a polyethylene stick, and subsequently placed in a constant temperature and humidity chamber at 37.5°C and 50% relative humidity for 24 hours for infiltration. The troxerutin content in the receiving chamber was then measured.

[0080] The concentration of troxerutin was determined by fluorescence spectroscopy (Ex: 360 nm, measurement range: 380–700 nm), and the concentration was quantified using the fluorescence intensity measured at 470 nm. The permeation rate of troxerutin was then calculated using the results and the volume of the extraction solvent. The results are shown in Table 3 below.

[0081] [Table 3]

[0082] As shown in Table 3 above, it can be confirmed that the permeability of troxerutin increased by approximately 2.4 times in the eutectic mixture of troxerutin and arginine glutamate compared to troxerutin alone. Therefore, the previously known problem with troxerutin, namely its poor skin permeability, has been resolved by this invention.

[0083] Based on Examples 1 to 3 of the present invention, it can be confirmed that the cosmetic composition of the present invention provides a low-irritant topical agent or a topical agent for skin soothing, thereby exhibiting the effects of inhibiting inflammation and relieving / reducing skin irritation.

[0084] Based on the foregoing description, those skilled in the art will understand that the present invention can be implemented in other specific forms without altering the technical concept or essential features of the invention. Relatedly, it should be understood that the embodiments described above are exemplary in all respects and not restrictive. The scope of the invention should be interpreted to include the meaning and scope of the following claims and all variations or modifications derived from their equivalents, and should not be construed as including only the detailed description above.

Claims

1. A cosmetic composition comprising an amino acid-amino acid eutectic mixture and troxerutin as an active ingredient.

2. The cosmetic composition according to claim 1, wherein, The content of the above-mentioned amino acid-amino acid eutectic mixture is from 0.001 to 50 parts by weight relative to 100 parts by weight of the whole composition.

3. The cosmetic composition according to claim 1, wherein, The aforementioned amino acid-amino acid eutectic mixtures include arginine glutamate eutectic mixtures or serine arginine eutectic mixtures.

4. The cosmetic composition according to claim 1, wherein, The content of troxerutin is 0.0001 to 2 parts by weight relative to 100 parts by weight of the whole composition.

5. The cosmetic composition according to claim 1, characterized in that, Compared with troxerutin alone, the above composition increases the skin penetration of troxerutin by 1.5 to 10 times.

6. The cosmetic composition according to any one of claims 1 to 5, wherein, The above cosmetic composition is used to soothe the skin.

7. An anti-inflammatory composition comprising an amino acid-amino acid eutectic mixture and troxerutin as an active ingredient.

Images